FAST

NCT01630083 📎

Regimen

Experimental
zolbetuximab + EOX (epirubicin + oxaliplatin + capecitabine)
Control
EOX alone

Population

CLDN18.2-positive advanced G/GEJ adenocarcinoma as first-line therapy

Key finding

mPFS/mOS HRs 0.44 and 0.55 (both p<0.0005); subgroup with >=70% moderate/strong CLDN18.2 PFS HR 0.38

Source: PMID 33610734

Timeline

    Guideline citations

    • NCCN GASTRIC (p.8)
    • CSCO GASTRIC 2025 (p.33)⚠️ OCR source